The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
[2];
- IAME, UMR 1137, INSERM, F-75018 Paris, France; Univ. Paris Diderot, Sorbonne Paris Cité, F-75018, Paris, France
- IAME, UMR 1137, INSERM, F-75018 Paris, France; Univ. Paris Diderot, Sorbonne Paris Cité, F-75018, Paris, France; Université Paris-Est, Hopital Henri Mondor, Creteil, France
- Loyola Univ. Medical Center, Department of Medicine, Maywood, Illinois, USA
- St. Joseph’s Hospital, Dignity Health, Phoenix, Arizona, USA
- National Inst. of Health (NIH), Laboratory of Immunoregulation, NIAID, Bethesda, MD, USA; Bethesda, MD (United States)
- Los Alamos, NM, USA; Los Alamos National Lab. (LANL), Theoretical Biology and Biophysics Group, Los Alamos, NM (United States)
High sustained virologic response (SVR) rates have been observed after 6 weeks of anti-HCV treatment using sofosbuvir, ledipasvir and a non-nucleoside polymerase-inhibitor (GS-9669) or a proteaseinhibitor (GS-9451) and after 12 weeks with sofosbuvir+ledipasvir. Here we analyze the viral kinetics observed during these treatments to decipher the origin of the rapid cure and to evaluate the possibility of further reducing treatment duration. We found that viral kinetics were surprisingly slow in all treatment groups and could not reproduce the high SVR rates observed. Based on experimental results suggesting that NS5A- or protease-inhibitors can generate non-infectious virus, we incorporated this effect into a mathematical model. We found that to predict observed SVR rates it was necessary to assume that ledipasvir, GS-9669 and GS-9451 rapidly reduce virus infectivity. We predicted with this model that 4 weeks of triple therapy could be sufficient to achieve SVR in patients with undetectable viremia at week 1, but would be suboptimal in general. In conclusion, the rapid cure rate achieved with these combinations is largely disconnected from viral loads measured during treatment. A model assuming that rapid cure is due to a drug effect of generating non-infectious virus could be a basis for future response guided therapy.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE
- Contributing Organization:
- National Institutes of Health
- Grant/Contract Number:
- AC52-06NA25396; R01-AI078881; R01-AI116868; R01-AI028433; R01-OD011095
- OSTI ID:
- 1643698
- Journal Information:
- Scientific Reports, Vol. 7, Issue 1; ISSN 2045-2322
- Publisher:
- Nature Publishing GroupCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
Similar Records
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
Modeling HCV cure after an ultra-short duration of therapy with direct acting agents